Cargando…

In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis

In the process of evaluating the effect of several plant extracts against Mycobacterium tuberculosis using the Microplate Alamar Blue Assay (MABA), an extract of Thai herb Alpinia galanga rhizome and its major component, 1′-acetoxychavicol acetate (ACA), exhibited marked anti-tuberculosis activity....

Descripción completa

Detalles Bibliográficos
Autores principales: Warit, Saradee, Rukseree, Kamolchanok, Prammananan, Therdsak, Hongmanee, Poonpilas, Billamas, Pamaree, Jaitrong, Sarinya, Chaiprasert, Angkana, Jaki, Birgit U., Pauli, Guido F., Franzblau, Scott G., Palittapongarnpim, Prasit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620519/
https://www.ncbi.nlm.nih.gov/pubmed/28927024
http://dx.doi.org/10.3390/scipharm85030032
_version_ 1783267601787387904
author Warit, Saradee
Rukseree, Kamolchanok
Prammananan, Therdsak
Hongmanee, Poonpilas
Billamas, Pamaree
Jaitrong, Sarinya
Chaiprasert, Angkana
Jaki, Birgit U.
Pauli, Guido F.
Franzblau, Scott G.
Palittapongarnpim, Prasit
author_facet Warit, Saradee
Rukseree, Kamolchanok
Prammananan, Therdsak
Hongmanee, Poonpilas
Billamas, Pamaree
Jaitrong, Sarinya
Chaiprasert, Angkana
Jaki, Birgit U.
Pauli, Guido F.
Franzblau, Scott G.
Palittapongarnpim, Prasit
author_sort Warit, Saradee
collection PubMed
description In the process of evaluating the effect of several plant extracts against Mycobacterium tuberculosis using the Microplate Alamar Blue Assay (MABA), an extract of Thai herb Alpinia galanga rhizome and its major component, 1′-acetoxychavicol acetate (ACA), exhibited marked anti-tuberculosis activity. The minimal inhibition concentrations (MICs) of the S-enantiomer of ACA (S-ACA) against M. tuberculosis H37Ra ATCC 25177 and H37Rv ATCC 27294 strains were 0.2 µg/mL and 0.7 µg/mL, respectively. More than 95% of 100 drug-sensitive and 50 drug-resistant mycobacterial clinical isolates were inhibited by extracted S-ACA at 1.0 µg/mL. All of the remaining isolates were inhibited at 2.0 µg/mL. In contrast to the S-enantiomer, synthetic racemic 1′-R,S-ACA (rac-ACA) showed MICs of 0.5 µg/mL and 2.7 µg/mL for M. tuberculosis H37Ra ATCC 25177 and H37Rv ATCC 27294, respectively, suggesting that the anti-tuberculosis effect might be primarily due to the S-form. These observations were in line with the MICs of rac-ACA against 98% of 93 drug-resistant clinical isolates, which showed the effective inhibitory dose at 2.0 µg/mL. After exposure to 2.7 µg/mL of rac-ACA for at least 3 h, the tubercle bacilli were completely killed. These demonstrated that ACA had potent anti-TB activity.
format Online
Article
Text
id pubmed-5620519
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-56205192017-10-06 In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis Warit, Saradee Rukseree, Kamolchanok Prammananan, Therdsak Hongmanee, Poonpilas Billamas, Pamaree Jaitrong, Sarinya Chaiprasert, Angkana Jaki, Birgit U. Pauli, Guido F. Franzblau, Scott G. Palittapongarnpim, Prasit Sci Pharm Article In the process of evaluating the effect of several plant extracts against Mycobacterium tuberculosis using the Microplate Alamar Blue Assay (MABA), an extract of Thai herb Alpinia galanga rhizome and its major component, 1′-acetoxychavicol acetate (ACA), exhibited marked anti-tuberculosis activity. The minimal inhibition concentrations (MICs) of the S-enantiomer of ACA (S-ACA) against M. tuberculosis H37Ra ATCC 25177 and H37Rv ATCC 27294 strains were 0.2 µg/mL and 0.7 µg/mL, respectively. More than 95% of 100 drug-sensitive and 50 drug-resistant mycobacterial clinical isolates were inhibited by extracted S-ACA at 1.0 µg/mL. All of the remaining isolates were inhibited at 2.0 µg/mL. In contrast to the S-enantiomer, synthetic racemic 1′-R,S-ACA (rac-ACA) showed MICs of 0.5 µg/mL and 2.7 µg/mL for M. tuberculosis H37Ra ATCC 25177 and H37Rv ATCC 27294, respectively, suggesting that the anti-tuberculosis effect might be primarily due to the S-form. These observations were in line with the MICs of rac-ACA against 98% of 93 drug-resistant clinical isolates, which showed the effective inhibitory dose at 2.0 µg/mL. After exposure to 2.7 µg/mL of rac-ACA for at least 3 h, the tubercle bacilli were completely killed. These demonstrated that ACA had potent anti-TB activity. MDPI 2017-09-18 2017 /pmc/articles/PMC5620519/ /pubmed/28927024 http://dx.doi.org/10.3390/scipharm85030032 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Warit, Saradee
Rukseree, Kamolchanok
Prammananan, Therdsak
Hongmanee, Poonpilas
Billamas, Pamaree
Jaitrong, Sarinya
Chaiprasert, Angkana
Jaki, Birgit U.
Pauli, Guido F.
Franzblau, Scott G.
Palittapongarnpim, Prasit
In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis
title In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis
title_full In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis
title_fullStr In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis
title_full_unstemmed In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis
title_short In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis
title_sort in vitro activities of enantiopure and racemic 1′-acetoxychavicol acetate against clinical isolates of mycobacterium tuberculosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620519/
https://www.ncbi.nlm.nih.gov/pubmed/28927024
http://dx.doi.org/10.3390/scipharm85030032
work_keys_str_mv AT waritsaradee invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis
AT ruksereekamolchanok invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis
AT prammananantherdsak invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis
AT hongmaneepoonpilas invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis
AT billamaspamaree invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis
AT jaitrongsarinya invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis
AT chaiprasertangkana invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis
AT jakibirgitu invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis
AT pauliguidof invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis
AT franzblauscottg invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis
AT palittapongarnpimprasit invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis